1,579 results on '"Werth, Victoria P."'
Search Results
2. Intravenously Administered Lecithin Liposomes: A Synthetic Antiatherogenic Lipid Particle
3. Skin disease in cutaneous lupus erythematosus
4. Management of cutaneous lupus erythematosus
5. Keratinocyte derived extracellular vesicles mediated crosstalk between epidermis and dermis in UVB-induced skin inflammation
6. Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective.
7. Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
8. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative
9. A national survey comparing practice patterns and residency training satisfaction for categorical dermatology versus combined internal medicine and dermatology trained physicians
10. Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative
11. OMERACT systemic lupus erythematosus domain survey
12. Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study
13. Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study
14. The physical and emotional impact of cutaneous dermatomyositis: a qualitative study
15. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce
16. Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database
17. Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus
18. Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro
19. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study
20. Diagnosis and management of pemphigus: Recommendations of an international panel of experts
21. Cutaneous Lupus
22. Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial
23. Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus
24. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial
25. How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
26. Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM
27. Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
28. Area Deprivation and Disease Severity in Adult Patients With Discoid Lupus Erythematosus.
29. Lupus community panel proposals for optimising clinical trials: 2018
30. Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference
31. Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus
32. An update on clinical trials for cutaneous lupus erythematosus
33. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank
34. Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?
35. Extracellular Vesicles in the Pathogenesis, Clinical Characterization, and Management of Dermatomyositis: A Narrative Review
36. The impact of hormones in autoimmune cutaneous diseases
37. Collaborative research in myositis-related disorders: MIHRA, a global shared community model
38. Expert consensus achieved on a working core outcome set for cutaneous lupus erythematosus research in survey following the 5th International Conference on Cutaneous Lupus Erythematosus (ICCLE)
39. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132
40. Clinical Features of Myositis: Skin Manifestations
41. Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis
42. Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness
43. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus
44. The effects of immunostimulatory herbal supplements on autoimmune skin diseases
45. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
46. The impact of hormones in autoimmune cutaneous diseases.
47. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
48. Effect of TNFα blockade on UVB-induced inflammatory cell migration and collagen loss in mice
49. Evaluating the effect of prior authorizations in patients with complex dermatologic conditions
50. International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.